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Abstract 
Background: Human immunodeficiency virus 2 infection is endemic in West Africa but is also found in parts of 
Europe, North and South America, and India where it is thought to have been introduced secondary to migration and 
commercial trade ties. It is less common than Human immunodeficiency virus 1, with differences in pathogenicity, 
lower rates of transmission, longer asymptomatic period and slower progression to acquired immunodeficiency syn-
drome. Human immunodeficiency virus 2 is also associated with diagnostic challenges given the lack of commercially 
available diagnostic tests, and management challenges given intrinsic resistance to many anti-retroviral therapies.
Case presentation: We describe a case of a 65 year old South Indian female, visiting her family in Australia, who 
presented with weight loss, pancytopaenia and generalised lymphadenopathy on a background of newly diagnosed 
congestive cardiac failure. Multiple investigations were performed to elucidate the cause of her presentation, with the 
eventual unexpected diagnosis of human immunodeficiency virus 2. She was commenced on anti-retroviral treat-
ment and made a remarkable recovery.
Conclusion: We describe the challenges associated with diagnosis of human immunodeficiency virus 2 due to lack 
of commercially available diagnostics, as well as the treatment and management challenges including the fact that 
human immunodeficiency virus 2 is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors. Human 
immunodeficiency virus 2 infection should be considered in patients who present with symptoms and signs that do 
not point towards a clear diagnosis, such as unexplained pancytopaenia or lymphadenopathy, and who have risk fac-
tors such as being from an endemic area or having had blood transfusions, especially prior to the commencement of 
blood-borne virus screening of blood donors.
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Background
The World Health Organisation estimates that 36.9 mil-
lion people are currently living with human immunode-
ficiency virus [1], of which approximately 1–2 million are 
thought to be infected with human immunodeficiency 
virus 2 (HIV-2). HIV-2 is less pathogenic than human 
immunodeficiency virus 1 (HIV-1) and the majority of 
HIV-2 infected individuals are long-term non-progres-
sors [2]. The transmission rate is thought to be much 
lower and there is a longer period of asymptomatic infec-
tion with a slower decline in CD4 cell counts [2, 3]. This 
ultimately means that there is a slower progression to 
acquired immunodeficiency syndrome (AIDS) and mor-
tality in HIV-2 infection is also more favourable com-
pared to HIV-1 [2, 3]. Diagnosis can be challenging due 
to the lack of commercially available diagnostic tests. 
Moreover, management can be difficult due to HIV-2 
being intrinsically resistance to several classes of antiret-
roviral medications and due to the lack of commercially 
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Case presentation
Mrs. M.R, a 65-year-old South Indian woman, visiting 
family in Australia, was admitted in January 2015 for the 
management of new congestive cardiac failure (CCF).
She had been recently discharged from a different 
hospital with symptoms consistent with community-
acquired pneumonia and managed with intravenous 
ceftriaxone and azithromycin followed by amoxicillin/
clavulanate and roxithromycin. Investigations at this time 
included a chest X-ray demonstrating right lung lower 
zone consolidation, and blood and sputum cultures were 
negative for routine pathogens; sputum acid-fast bacilli 
(AFB) smears were negative. She subsequently developed 
worsening bilateral peripheral limb oedema, increas-
ing exertional dyspnoea and paroxysmal nocturnal 
dyspnoea, and was admitted to our hospital for further 
management. Clinical examination was consistent with 
congestive cardiac failure with evidence of atrial fibrilla-
tion. Additionally the patient was found to have cervical 
and parotid lymphadenopathy measuring approximately 
1–2 cm in size.
Her past medical history included ischaemic heart 
disease, atrial fibrillation, hypertension, osteoarthritis, 
asthma, herpes zoster (6 months prior to admission), lap-
arotomy in 1968 for an unclear indication, and total hys-
terectomy in 1991. Further history revealed a 6-month 
history of 5  kg weight loss with no anorexia, and she 
denied fevers and night sweats. There was no other travel 
history besides to Australia. She had been married since 
the age of 19 and denied other sexual partners. There was 
no history of tattoos or injecting drug use. She had no 
animal contact or gardening activities.
Initial laboratory investigations revealed pancytope-
nia with a normocytic anaemia: haemoglobin 80  g/L 
(115–165 g/L), mean cell volume 84 fL (80–96 fL), white 
cell count 3.0 × 109/L (4–11 × 109/L), with normal neu-
trophils 2.5  ×  109/L (2–7.5  ×  109/L) and lymphopenia 
0.2 × 109/L (1–4 × 109/L), and platelets 55 × 109/L (150–
400 × 109/L). Her chest X-ray was consistent with fluid 
overload with bilateral pleural effusions and there was 
evidence of right lung lower zone consolidation.
Given the pancytopenia, lymphadenopathy and weight 
loss, Mrs. M.R proceeded to have computerised tomog-
raphy (CT) of the neck, chest, abdomen and pelvis. 
This revealed widespread mediastinal, hilar and perito-
neal lymphadenopathy as well as multiple peripherally 
enhancing cystic lesions within the right parotid gland, 
raising the possibility of tuberculous adenitis. A positron 
emission tomography scan demonstrated metabolically 
active retroperitoneal, mesenteric and inguinal lymph 
nodes. Transthoracic echocardiography revealed nor-
mal left ventricular size and function, impaired right 
ventricular systolic function as well as diastolic dysfunc-
tion, and severe pulmonary hypertension (pulmonary 
artery systolic pressure 57  mmHg  +  right atrial pres-
sure). CT pulmonary angiogram did not reveal evidence 
of pulmonary embolus, and screening tests for connec-
tive tissue disorders as a cause for secondary pulmonary 
hypertension were unremarkable. In view of her country 
of origin and respiratory symptoms, sputum AFB smears 
were repeated and were negative. Quantiferon-Gold test-
ing was indeterminate.
Given her unexplained lymphadenopathy and weight 
loss, Mrs. M.R went on to have human immunodefi-
ciency virus testing. The HIV-1/2 enzyme immunosorb-
ent assay (EIA) (Roche) at our hospital was unexpectedly 
strongly positive on two occasions and the sample was 
sent to the Victorian Infectious Diseases Reference Lab-
oratory for confirmation. The HIV-1/2 EIA using dif-
ferent platforms (Genscreen and Liaison XL) was also 
positive but the HIV-1 p24 antigen was negative. The 
HIV-1 western blot was negative. This prompted testing 
for HIV-2, performed at the National Reference Labora-
tory, using an in-house HIV-2 western blot (Fig.  1) and 
the BioRad Multispot EIA assay, which is able to dif-
ferentiate between HIV-1 and HIV-2 antibodies. Both 
tests confirmed HIV-2 infection. HIV-2 viral load (VL) 
was performed using a research-based assay and was 
detected at 3260  copies/mL. Resistance testing dem-
onstrated susceptibility to all protease inhibitors and 
nucleoside reverse transcriptase inhibitors; resistance to 
non-nucleoside reverse transcriptase inhibitors was con-
sistent with HIV-2. Her CD4 T cell count was 118 cells/
µL (17%) (650–2000 cells/µL; 35–59%). Further question-
ing revealed the patient received a blood transfusion in 
1991 during her hysterectomy in India; no other risk fac-
tors for HIV infection were determined, and her husband 
tested negative for HIV-1 and HIV-2.
Given this new diagnosis of HIV-2 infection, a number 
of potential differential diagnoses were considered for 
Mrs. M.R’s pancytopenia, widespread lymphadenopa-
thy, weight loss and ongoing respiratory issues. Multiple 
lymph node aspirates and core biopsies, bone marrow 
aspirate and trephine, and bronchoscopy were performed 
and did not reveal a microbiological or haematological 
diagnosis; investigations for mycobacterial, fungal and 
opportunistic infections were negative on all specimens.
She was commenced on anti-retroviral therapy with 
fixed-dose combination emtricitabine 200 mg +  tenofo-
vir 300 mg daily and ritonavir (200 mg)-boosted lopina-
vir 800 mg daily, a regimen widely available in India. She 
was also commenced on trimethoprim-sulfamethoxazole 
for Pneumocystis jiroveci prophylaxis. Within 2  months 
her VL was undetectable and her CD4 cell count was 
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improving, after an initial decline. Her pancytopenia 
improved and her lymphadenopathy regressed over the 
next 2 months and these were subsequently attributed to 
HIV-2 infection.
Mrs. M.R continued on anti-retroviral treatment and 
remained well until she returned to India.
Discussion
The World Health Organisation estimates that 36.9 mil-
lion people are currently living with HIV [1], of which 
approximately 1–2 million are thought to be infected 
with HIV-2. HIV-2 was first isolated in humans in Sen-
egal in 1984 [4] and originated from sooty mangabeys. 
It is endemic in West Africa but is also found in parts of 
Europe, North and South America, and India where it is 
thought to have been introduced secondary to migration 
and commercial trade ties [2]. Its prevalence is very rare 
in Australia [5].
Phylogenetic analysis confirms that HIV-1 and -2 are 
genetically distinct [4]. HIV-2 is less pathogenic than 
HIV-1 and the majority of HIV-2 infected individuals 
are long-term non-progressors [2]. Although transmis-
sion routes for HIV-2 are the same as for HIV-1, the 
transmission rate is thought to be much lower, with het-
erosexual transmission rates 5- to 10-fold lower [6] and 
vertical transmission rates 6- to 30-fold lower [2] com-
pared with HIV-1 infection. There is a longer period of 
asymptomatic infection and slower decline in CD4 cell 
counts, thought to be secondary to lower levels of plasma 
viraemia [3]. This ultimately means that there is a slower 
progression to acquired immunodeficiency syndrome 
and only 20–30% of HIV-2 infected individuals go on 
Fig. 1 Mrs M.R’s HIV-1 and HIV-2 western blot assays. a HIV-1 western blot at the Victorian Infectious Diseases Reference Laboratory. Lane 1 control 
sample; lane 2 interpretation schema; lane 3 patient sample. Black arrow indicates positive band corresponding to HIV-2. Multiple bands detected in 
lane 3 do not match HIV-1 proteins. b HIV-2 specific western blot at the National Reference Laboratory. Lane 1 quality control (QC) 1:2048 dilution; 
lane 2 QC 1:4096 dilution; lane 3 QC 1:8192 dilution; lane 4 patient sample (highlighted in red); lane 5 negative control; lane 6 positive control with 
interpretation schema. Note patient has multiple HIV-2 bands matching QC and positive control samples
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to develop AIDS [2, 3]. Mortality in HIV-2 infection is 
also more favourable compared to HIV-1 at CD4 counts 
above 200 cells/μL, however this advantage is lost when 
CD4 counts drop below 200 cells/μL [2].
HIV diagnosis and management guidelines from the 
US [7] recommend testing for HIV-2 in specific patient 
populations (Table 1). The differentiation between HIV-1 
and HIV-2 infection is important given the differing 
natural histories of the disease and subsequent choice of 
anti-retroviral therapy (ART). The HIV-1/HIV-2 type-
differentiation assay is only available in a research setting 
in Australia and assisted in the diagnosis in our patient. 
A western blot is performed for confirmation of HIV-2. 
Unfortunately, HIV-1 western blots may fully or partially 
cross react with HIV-2, giving positive, indeterminate 
or negative results that could lead to an incorrect diag-
nosis of HIV-1 or a missed diagnosis of HIV-2. In-house 
assays for HIV-2 viral load in the US and Australia have 
not been approved by regulatory authorities. Therefore, 
monitoring of treatment response in HIV-2 is difficult 
due to the lack of commercially available viral load moni-
toring and genotypic resistance assays.
The goals of therapy in HIV-2 are similar to HIV-1, 
however the choice of anti-retroviral therapy differs for 
HIV-2. There are no randomised controlled trials to 
assess the efficacy of specific combination ART in treat-
ment-naïve HIV-2 infected patients.
HIV 2 is intrinsically resistant to non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) and to the 
fusion inhibitor enfuvirtide [2]. Both these classes of 
ART are not recommended for treatment of HIV-2 infec-
tion. In vitro and small observational studies have shown 
that nucleoside reverse transcriptase inhibitors (NRTIs) 
and protease inhibitors (PIs) are active against HIV-2 
[2]. Among PIs, lopinavir, saquinavir and darunavir have 
been shown to be most potent [8]. HIV-2 appears to be 
susceptible to the integrase strand transfer inhibitors 
(INSTIs), and recent trials have shown good responses 
[9]. However, there are less long-term data compared to 
PIs and emergence of on-treatment mutations have been 
reported. As HIV-2 can use several co-receptors to enter 
cells, some with greater affinity than CCR5, the efficacy 
of the CCR5 antagonist maraviroc is uncertain [2]. Cur-
rent British and US guidelines suggest starting a NRTI 
backbone with a boosted PI [10, 11] or INSTI [11], and 
these are reflected in Australian guidelines [5].
Conclusion
In conclusion HIV-2 infection was an unexpected diag-
nosis in Mrs M.R, with the only risk factors identified 
being a blood transfusion in 1991 and being from India 
where HIV-2 is not uncommon. We did not find any 
evidence of an opportunistic infection or lymphopro-
liferative disorder to explain her lymphadenopathy and 
cytopenias, and it was assumed these were HIV-related 
in the context of advanced disease. Investigations to look 
for other causes of her pulmonary hypertension were also 
negative and it was thought this was possibly related to 
advanced HIV-2 infection and pre-existing ischaemic 
heart disease. Clinicians need to be aware of HIV-2 as 
a diagnosis and modern algorithms should incorporate 
testing. Although HIV-2 infection is uncommon, patients 
have a prolonged asymptomatic phase and may present 
late due to its lower pathogenicity. HIV-2 viral load and 
genotypic resistance assays are not commercially avail-
able, making testing as well as monitoring treatment 
response difficult. Management of HIV-2 differs from 
HIV-1; NNRTIs and fusion inhibitors cannot be used, 
and current guidelines recommend the use of 2 NRTIs 
and a boosted PI or INSTI.
This case also highlights the importance of undertaking 
HIV testing in patients with a constellation of symptoms 
and signs that do not point towards a clear diagnosis and 
to consider HIV-2 in patients who come from an endemic 
area or have other risk factors such as blood transfusions 
and sexual contact with someone from an endemic area.
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Table 1 Differentiation of  HIV-1 and  HIV-2, based on  the 
New York State Department of Health AIDS Institute
1 Originated or have travelled to HIV-2 endemic area
2 Received medical care, injections, immunisations, phlebotomy, 
surgery or blood products in an HIV-2 endemic area
3 Sexual or needle sharing contact with persons who are infected 
with HIV-2 or from a HIV-2 endemic area
4 Born to a mother with HIV-2 infection
5 Opportunistic infections or other clinical symptoms of HIV/AIDS 
but tested negative or indeterminate for HIV-1
6 Multiple HIV-1 indeterminate antibody test results
7 Unusual pattern/indeterminate HIV-1 Western Blot
8 Confirmed diagnosis of HIV-1 but undetectable viral load incom-
patible with clinical or immunological status
http://www.hivguidelines.org/clinical-guidelines/adults/human-
immunodeficiency-virus-type-2-hiv-2/
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